TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35777275
Drug: 324 mg
Normalized name: aspirin 324 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 324 mg of VTS‐Aspirin™ and 0.5 mg/kg of oral ketamine (AOK)
Study: 35777275
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg of oral ketamine (OK)
Study: 32270632
Drug: Midnight-noon ebb-flow
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midnight-noon ebb-flow acupuncture combined with rehabilitation therapy
Study: 32270632
Drug: Rehabilitation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation therapy (control group)
Study: 34034365
Drug: High-TSH group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-TSH group (target TSH levels between 2.0 and 7.99 μIU/mL)
Study: 34034365
Drug: Low-TSH group
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-TSH group (target TSH levels between 0.3 and 1.99 μIU/mL)
Study: 36402359
Drug: High-dose IMRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IMRT (59.4 Gy)
Study: 36402359
Drug: Standard-dose IMRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose IMRT (50.4 Gy)
Study: 33555374
Drug: Fibre-enriched Leberkas
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre-enriched Leberkas meal (19.2 g of wheat fibre and resistant dextrin, fat- and energy-reduced by 30%)
Study: 35470188
Drug: Primary radiotherapy
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary radiotherapy combined with S‐1 and nedaplatin chemotherapy (50.4 Gy + 4-6 cycles of S-1 and NPD)
Study: 35470188
Drug: S‐1 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐1 and nedaplatin chemotherapy (4-6 cycles)
Study: 34810107
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training + sensorimotor physical therapy (45 min sensorimotor + 15 min inspiratory muscle training for 18 sessions over six weeks)
Study: 34041615
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (six-step music therapy), n=50
Study: 32205463
Drug: Nivolumab 1
Normalized name: nivolumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg + RT (30 Gy in 10 fractions)
Study: 32205463
Drug: Nivolumab 1
Normalized name: nivolumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg + RT (27 Gy in 3 fractions)
Study: 34061144
Drug: Reduced-dose prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose prednisolone (0.5 mg/kg/d) plus rituximab (375 mg/m2/wk, 4 doses)
Study: 34061144
Drug: High-dose prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prednisolone (1 mg/kg/d) plus rituximab
Study: 34061144
Drug: Reduced-dose prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose prednisolone (0.5 mg/kg/d) plus rituximab
Study: 32334034
Drug: Concurrent weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Concurrent weekly cisplatin 40 mg/m2 with escalating doses of gemcitabine (50, 75, 100, or 125 mg/m2) plus IG‐IMRT (45‐47.6 Gy, 25‐28 fractions to the pelvis ± paraortic nodes with simultaneous nodal boost to 53.2‐59.4 Gy, 28 fractions)
Study: 32334034
Drug: IG‐IMRT with
Approvals — FDA: no, EMA: no, PMDA: no
Description: IG‐IMRT with concurrent chemotherapy
Study: 33171113
Drug: Leukocyte‐ and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocyte‐ and platelet‐rich fibrin (L‐PRF)
Study: 35236391
Drug: morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine sulphate 5 mg twice daily for 14 days
Study: 35236391
Drug: placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo twice daily
Study: 32633901
Drug: Attention Bias
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention Bias Modification (ABM) - eight sessions of twice-weekly training (n=49)
Study: 32216084
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (SXB) administered in two equally divided doses over two nights; dose 1 was half of dose 2, administered > 2 hours after the evening meal and ≥ 4 hours after dose 1.
Study: 36054974
Drug: Cyproheptadine HCl
Normalized name: cyproheptadine HCl
DrugBank: Cyproheptadine (DB00434)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyproheptadine HCl (4 mg BID to 8 mg TID over 3 weeks)
Study: 36054974
Drug: Placebo (matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matched doses)
Study: 32803720
Drug: First-line doublet
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line doublet chemotherapy with bevacizumab
Study: 32803720
Drug: First-line doublet
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line doublet chemotherapy without bevacizumab
Study: 33246371
Drug: Thinking for
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thinking for a Change cognitive behavioral program with greater program dosage
Study: 33246371
Drug: Traditional classroom
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional classroom administration of the Thinking for a Change program
Study: 36121664
Drug: Men with
Normalized name: Peptamen with Prebio Vanilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men with PSA ≥3 to 4 ng/ml
Study: 36121664
Drug: Men with
Normalized name: Peptamen with Prebio Vanilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men with a history of digital rectal examination or PSA testing prior to recruitment
Study: 33611087
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg regular, oral sustained-release morphine twice daily for four weeks
Study: 34895843
Drug: Posaconazole with
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole with other antifungal prophylaxis (Group-3, n = 142)
Study: 34895843
Drug: Other antifungal
Normalized name: Other antifungals for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antifungal prophylaxis (Group-4, n = 91)
Study: 34895843
Drug: No antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antifungal prophylaxis (Group-1, n = 203)
Study: 35207411
Drug: Melatonin 2
Normalized name: melatonin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 2 mg administered orally for 12 weeks
Study: 34663379
Drug: XR-naltrexone treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: XR-naltrexone treatment
Study: 33191260
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 650 mg
Study: 32219517
Drug: CAM users
Normalized name: phendimetrazine tartrate Oral Tablet [Cam-Metrazine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAM users declining conventional cancer therapy (CCT)
Study: 33159163
Drug: Fish-oil (FO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil (FO) supplementation (215 mg DHA + 285 mg EPA)
Study: 33159163
Drug: Control corn-oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control corn-oil capsules (without n‐3 LCPs)
Study: 37614053
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination therapy (telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg)
Study: 37614053
Drug: Dual combination
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual combination therapy (telmisartan 40 mg/amlodipine 5 mg)
Study: 33787382
Drug: Early steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early steroid withdrawal (ESW)
Study: 35473650
Drug: Present-centered group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present-centered group therapy (TAU)
Study: 32197342
Drug: Five-day intensive
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-day intensive holiday cooking program followed by six weeks of weekly meal kits with Facebook support groups
Study: 35239885
Drug: Integrated experiential
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated experiential learning of traditional Chinese and Western medicine
Study: 34508839
Drug: GLS in
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GLS in patients on baseline angiotensin convertase enzyme inhibitors
Study: 34508839
Drug: GLS in
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GLS in patients on baseline beta-blockers
Study: 32940847
Drug: CEF (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEF (cyclophosphamide 75 mg/m2 orally for 14 days, epirubicin 60 mg/m2 and fluorouracil IV days one and eight for six cycles)
Study: 32940847
Drug: ddEC/T (dose-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: ddEC/T (dose-dense epirubicin 120 mg/m2 and cyclophosphamide IV every 2 weeks for six cycles with concurrent G-CSF then paclitaxel every 2 weeks for four cycles)
Study: 32940847
Drug: AC/T (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC/T (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 3 weeks for four cycles then four cycles q3 weekly paclitaxel 175 mg/m2)
Study: 34034067
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (0.5-0.75 mg/kg) administered over 1-2 weeks, with four infusions.
Study: 32152169
Drug: 430 mg
Normalized name: urea 430 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 430 mg olive oil (placebo)
Study: 35922522
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose IV salbutamol (15 mcg/kg, max. 750 mcg)
Study: 35922522
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose IV salbutamol
Study: 34726262
Drug: Nemolizumab 60
Normalized name: Nemolizumab
DrugBank: Nemolizumab (DB15252)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemolizumab 60 mg every 4 weeks (Q4W) with concomitant topical treatments
Study: 34810349
Drug: Simvastatin Gel
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin Gel (SG)
Study: 36476355
Drug: Carrier oil
Normalized name: Carrier oil-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrier oil inhalation (Control group, n=48)
Study: 35140195
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg per day from admission to discharge)
Study: 34714194
Drug: Nifedipine gastrointestinal
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine gastrointestinal therapeutic system (GITS, 30‐60 mg)
Study: 34714194
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (both amlodipine and nifedipine)
Study: 32857027
Drug: Collagen-based bioinductive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen-based bioinductive implant
Study: 34261489
Drug: Lettuce (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lettuce (100 g) with moderately high-fat meal
Study: 34261489
Drug: Watercress (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watercress (100 g) with moderately high-fat meal
Study: 616871171
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg atorvastatin once daily for 6 months
Study: 36271753
Drug: office-based vergence/accommodative
Approvals — FDA: no, EMA: no, PMDA: no
Description: office-based vergence/accommodative therapy
Study: 33884674
Drug: High hemoglobin
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High hemoglobin target (>12.5 g/dL)
Study: 33884674
Drug: Low hemoglobin
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low hemoglobin target (<10.5 g/dL)
Study: 35534590
Drug: 0.3 M
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 M sodium chloride solution
Study: 35534590
Drug: 0.5 M
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 M sodium chloride solution
Study: 36164077
Drug: Loncastuximab tesirine
Normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loncastuximab tesirine (0.15 mg/kg) + rituximab (375 mg/m2) for 2 cycles, then Loncastuximab (0.075 mg/kg) + rituximab (375 mg/m2) for up to 6 additional cycles.
Study: 33131170
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser combined with L-GFs
Study: 35769842
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1200 mg daily for 10 days
Study: 35986297
Drug: Acupuncture based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture based on syndrome differentiation with donepezil (5 mg/day) for 12 weeks
Study: 35970518
Drug: Fluticasone furoate/umeclidinium/vilanterol
Normalized name: Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg
Study: 32162970
Drug: Fluticasone furoate/umeclidinium/vilanterol
Normalized name: Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/umeclidinium/vilanterol (FF/VI) 100/25 μg
Study: 34774885
Drug: FDY-5301 (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDY-5301 (2.0 mg/kg)
Study: 34774885
Drug: FDY-5301 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDY-5301 (0.5 mg/kg and 1.0 mg/kg)
Study: 34621380
Drug: Asthma patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asthma patients with CC genotype
Study: 33526271
Drug: SURE RAB™
Approvals — FDA: no, EMA: no, PMDA: no
Description: SURE RAB™ (inactivated cell culture derived rabies vaccine)
Study: 33526271
Drug: VERORAB (approved
Approvals — FDA: no, EMA: no, PMDA: no
Description: VERORAB (approved rabies vaccine)
Study: 34989778
Drug: 5-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-day regimen of postoperative prophylactic intravenous cephalosporin (cefazolin or cefuroxime)
Study: 34989778
Drug: 1-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-day regimen of postoperative prophylactic intravenous cephalosporin (cefazolin or cefuroxime)
Study: 33073449
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g day−1 for 5 days)
Study: 33348935
Drug: PRP intradermal
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP intradermal injection
Study: 33348935
Drug: FCL followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FCL followed by topical PRP
Study: 33348935
Drug: Microneedling followed
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedling followed by topical PRP
Study: 35781816
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg VE
Study: 35781816
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg VE
Study: 35781816
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg VE
Study: 35781816
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg VE
Study: 33654316
Drug: PVP-I 0.6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVP-I 0.6% eye drops four times/daily for 20 days
Study: 33654316
Drug: Hyaluronate-based tear
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronate-based tear substitutes four times/daily for 20 days
Study: 32246682
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac (50 mg twice daily)
Study: 32246682
Drug: Transdermal diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal diclofenac patch (100 mg once daily)
Study: 33038280
Drug: Soluble leptin
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble leptin receptor (sOB-R)
Study: 33095849
Drug: Systemic heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic heparin anticoagulation (n=296)
Study: 35142643
Drug: DRL_TZ (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRL_TZ (6 mg/kg, single intravenous infusion)
Study: 35142643
Drug: Herceptin® (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herceptin® (6 mg/kg, single intravenous infusion)
Study: 34444121
Drug: Nonsurgical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical periodontal treatment (NSPT) with community health worker (CHW) strategy
Study: 36151343
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation (MBP) with oral antibiotics (OA) using Alfa Normix®
Study: 36151343
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation (MBP) alone
Study: 32502588
Drug: Tapinarof cream
Normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapinarof cream 0.5%
Study: 32502588
Drug: Tapinarof cream
Normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapinarof cream 1%
Study: 32502588
Drug: Tapinarof cream
Normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapinarof cream 0.5% once or twice daily
Study: 34216454
Drug: Lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1% with epinephrine (40 ml)
Study: 34216454
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% with epinephrine (20 ml)
Study: 36307989
Drug: Topical gentamicin
Normalized name: gentamicin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gentamicin cream delivered via the platform wound device (PWD)
Study: 36153456
Drug: Medication +
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication + Thunder-fire moxibustion
Study: 33401330
Drug: Prasugrel standard-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel standard-dose (10 mg)
Study: 33401330
Drug: Prasugrel de-escalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel de-escalation strategy (5 mg and PFT-guided)
Study: 35958679
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg esketamine
Study: 33352584
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (8 IU, self-administered up to thrice daily for 4 weeks)
Study: 33125189
Drug: MK-1654 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1654 (100 mg, 300 mg intramuscular; 300 mg, 1000 mg, 3000 mg intravenous)
Study: 32533791
Drug: 2 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg.kg‐1 intranasal dexmedetomidine
Study: 32533791
Drug: 1 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg.kg‐1 intravenous dexmedetomidine
Study: 36107220
Drug: Rifampin 600
Normalized name: rifampin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg
Study: 36274185
Drug: CBTv-based EMI
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBTv-based EMI in addition to treatment as usual (TAU)
Study: 33394323
Drug: Solriamfetol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol treatment for 12 weeks
Study: 35120890
Drug: Inhaled diesel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled diesel exhaust (DE) at 300 μg PM2.5/m3 for 2 hours
Study: 35120890
Drug: Inhaled diesel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled diesel exhaust (DE) at 20, 50, or 150 μg PM2.5/m3 for 4 hours
Study: 35120890
Drug: Inhaled diesel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled diesel exhaust (DE)
Study: 35051725
Drug: Cisplatin-gemcitabine (CG)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-gemcitabine (CG) followed by gemcitabine (G) maintenance for patients with objective response (OR) or switch to pemetrexed (P) for patients with stable disease (SD)
Study: 36101997
Drug: Rutin 500
Normalized name: rutin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rutin 500 mg per day for 3 months
Study: 33884889
Drug: High-sensitivity cardiac
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity cardiac troponin I ≥5 ng/L
Study: 33884889
Drug: BNP ≥100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP ≥100 pg/mL
Study: 33884889
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of high-sensitivity cardiac troponin I ≥5 ng/L and BNP ≥100 pg/mL
Study: 34263472
Drug: Edasalonexent (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edasalonexent (100 mg or 250 mg softgel capsules)
Study: 32651292
Drug: 200/50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200/50 mg dispersible levodopa‐benserazide (dopaminergic challenge)
Study: 616689159
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy (specifics not provided)